JAK2 and MPL mutations are recurrent in myeloproliferative neoplasms (MPNs). A JAK2 mutation, primarily JAK2V617F, is almost invariably associated with polycythemia vera (PV). However, JAK2V617F also occurs in the majority of patients with essential thrombocythemia (ET) or primary myelofibrosis (PMF) as well as in a much smaller percentage of those with other MPNs. The mechanism(s) behind this one allele-multiple phenotypes phenomenon has not been fully elucidated. The issue is further confounded by the presence of marked variation in JAK2V617F allele burden among mutation-positive patients. In the current communication, we discuss potential mechanisms for phenotypic diversity among JAK2V617F-positive MPNs as well as review the current literature in regard to genotype-phenotype correlations (that is clinical correlates and prognostic significance) in the context of both the presence or absence of the mutation (ET and PMF) and its allele burden (PV, ET and PMF).
Introduction
The discovery of mutations in JAK2, which includes the JAK2V617F point mutation located in exon 14 [1] [2] [3] [4] as well as those occurring in exon 12 5 , and in MPL 6 (MPLW515L/K 7 and others recently reported such as the W515A, 8 S204P 9 and the S505N 10 originally described in inherited familial thrombocytosis 11 ), has allowed a tremendous advance in the understanding of pathophysiology of the classic BCR-ABL-negative myeloproliferative neoplasms (MPNs). 12 From the clinical point of view, availability of these novel molecular markers has improved and simplified the diagnostic approach to these disorders, eventually resulting in a proposal for revision of their World Health Organization (WHO) diagnostic criteria, in which the presence of any of these molecular abnormalities is considered as a major diagnostic criterion. 10 In contrast, it is still largely debated as to what extent genetic abnormalities in JAK2 or MPL are involved in specific phenotypes among MPNs, 13 and particularly whether they deserve relevance for patient risk stratification.
It is the aim of this manuscript to review available data concerning the clinical correlates and prognostic significance of JAK2V617F mutation in essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF). First, we will address the comparisons between V617F-positive and -negative ET or PMF; second, we will review the relevance of mutant allele burden in PV, ET and PMF.
The puzzle of a single mutant allele in different clinical phenotypes
One of the most important open questions is how, notwithstanding the substantial phenotypic mimicry between them, the V617F mutation might be involved in three distinct phenotypes: PV, ET and PMF. The expression of JAK2V617F in cytokinedependent cell lines confers cytokine independence and cytokine hypersensitivity through the constitutive activation of STAT5, Akt and ERK-dependent pathways (for a review, see Levine et al. 14 
and Vainchenker and Constantinescu 15
). The in vivo counterpart of this phenomenon is represented by the formation of endogenous erythroid colonies typically observed in patients with PV, 16 where it has also been employed for diagnostic purposes. The presence of JAK2V617F correlated with endogenous erythroid colony formation 4 and, conversely, the expression of mutant JAK2 in human progenitor cells induced Epo-independent growth in vitro. 17 Hematopoietic progenitors from patients with PV or the related MPNs have also been reported to be hypersensitive to interleukin-3, insulin growth factor-1, stem cell factor, granulocyte-macrophage colony-stimulating factor and thrombopoietin. 18 Similarly, although less commonly reported, the autonomous growth of myeloid and megakaryocytic progenitors in such patients is also well documented. 19 The facts that (i) JAK2 normally associates with the cytosolic domain of several cytokine receptors 20 and is a key effector for cytokine receptor signaling, and that (ii) JAK2V617F is a constitutively phosphorylated tyrosine kinase help to explain the associated cytokine independent/hypersensitive growth. However, until now, there is little evidence to suggest that JAK2V617F occurs in different progenitors as the mechanism underlying phenotypic variability. Jamieson et al. 21 have demonstrated that the mutation was present in flow cytometrypurified populations of hematopoietic stem cells, common myeloid progenitors, granulocyte/macrophage progenitors and megakaryocytic/erythroid progenitors. Similar findings in different hematopoietic cell lineages have been reported in PV and PMF patients [22] [23] [24] [25] [26] although lymphoid cells were involved in only a proportion of the patients; 27 furthermore, the occurrence of the mutation in a myelo-lymphoid progenitor in patients with PV and PMF has been demonstrated. 28 Mitotic recombination of the short arm of chromosome 9, resulting in homozygosity for the V617F allele at the single cell level, happens in about 30% of patients with PV and PMF as compared to only 2-4% of those with ET. The term 'homozygous' is currently employed to indicate those patients in whom the level of mutant allele in the test sample is greater than 50% of total JAK2 (mutant plus wild type), notwithstanding the fact that single colony studies have revealed a pure mutant allele state in virtually all PV patients, including those assigned 'heterozygous' mutational status according to allele burden measured in granulocyte-derived DNA. Conversely, homozygosity at the single cell level is infrequent in ET. 17, 29 Duplication of the mutant allele in homozygous cells might result in a higher level of JAK-STAT activation than that seen in cells with both mutant and wild-type alleles, as indirectly supported by the fact that the expression level of a number of JAK2-target genes was found to be mutant allele dose-dependent in both granulocytes and CD34 þ cells. These genes include, among others, PRV-1, 30-33 NF-E2, 15-17 the gene encoding leukocyte alkaline phosphatase, 34 and HMGA2. 35 In other words, loss of competition between normal and mutant allele might enhance the effect of mutant protein, although formal proof of it is still lacking. 1 In addition, impaired/enhanced interaction of JAK2V617F with relevant cellular substrates might contribute to the derangement of cellular function, as exemplified by the loss of inhibitory regulation exerted by the suppressor of cytokine signaling-3 (SOCS3) in mutant cells expressing the V617F allele. 36 The 'dosage' hypothesis is also supported by observations in animal models. The adoptive transfer of marrow cells transduced with a retrovirus-expressing JAK2V617F in irradiated recipient mice invariably resulted in the development of erythrocytosis, 1, [37] [38] [39] [40] usually accompanied by leukocytosis and splenomegaly, and eventually followed by changes suggestive of myelofibrotic transformation. [37] [38] [39] [40] In contrast, these mice did not develop thrombocytosis, notwithstanding an increased proliferation of megakaryocytes in their bone marrow. However, Lacout et al. 38 observed thrombocytosis in a subgroup of mice expressing a low level of transduced gene and hypothesized that high levels of JAK2 kinase activity actually favored an erythroid phenotype, whereas low levels would favor a megakaryocytic phenotype. The interpretation of data from animal models is complicated by the fact that levels of mutant JAK2 mRNA obtained following retroviral transduction of the cells are extremely high, in the order of 10-to 40-fold the endogenous wild-type JAK2. Recently, JAK2V617F transgenic mice have been generated, obtaining two lines of transgenic mice that expressed levels of JAK2V617F mRNA corresponding to 0.45-and 1.35-fold, respectively, that of endogenous wild-type JAK2. 41 In addition, a new inducible transgenic mouse model, using a bacterial artificial chromosome containing JAK2V617F under the control of JAK2 promoter, has been developed by the group of R Skoda. 42 In both models, the mice expressing lower levels of mutant JAK2 displayed a phenotype reminiscent of ET, with thrombocytosis and minimal erythrocytosis, whereas in the animals that presented higher levels of mutant JAK2, a PV-like picture developed without thrombocytosis.
However, even the 'dosage' effect does not entirely explain the phenotypic heterogeneity of MPNs. Indeed, intriguing differences were observed depending on the genetic background of the mice; the expression of JAK2V617F in Balb/c mice resulted in marked leukocytosis and bone marrow reticulin fibrosis, whereas in C57Bl/6 mice leukocytosis was minimal and fibrosis was limited to the spleen. 37, 40 These observations are in support of the role of unique host genetic characteristics that might act as modifiers of the phenotype in concert with the JAK2V617F mutation.
14,43 Interestingly, Pardanani et al. 44 have recently identified single nucleotide polymorphisms in JAK2 that were associated with the PV phenotype.
In conclusion, there is enough experimental evidence, both in vitro and in vivo, to support a direct cause-effect relationship for the JAK2V617F mutation in the pathogenesis of PV and possibly the related MPNs. Furthermore, the V617F allele dose contributes to disease phenotype, probably in concert with additional individual variables. Finally, the possibility that other clonal events occurring in pre-JAK2 mutated cells and favoring the acquisition of the V617F allele contribute to the pathogenesis of MPNs is supported by several observations, [45] [46] [47] [48] [49] [50] but it still needs to be substantiated. 51 The case of patients with ET or PMF: to be mutated or not
The most reproducible phenotypic effects ascribed to the presence of JAK2V617F mutation have been reported in studies dealing with ET patients (please refer to Table 1 ). According to the presence/absence of the V617F allele, ET has been divided into two distinct subtypes, the mutated patients being characterized by higher hemoglobin level and white cell count, lower platelet count, an increased risk of venous thrombosis and a hypercellular bone marrow with stimulated myelopoiesis. 52 However, the association with thrombosis is controversial, as elaborated in Table 1 . Overall, these features have been interpreted as suggestive of a biologically distinct 'forme fruste' of PV; this is further supported by the fact that no conversion from a JAK2 wild type to a V617F mutated ET has been reported yet, thus indicating that wild-type ET is not a pre-JAK2V617F phase of the disease. 46 In PMF, the presence of JAK2V617F was associated with inferior survival in a multicenter study of 152 patients despite the fact that mutated patients were less likely to require red blood cell transfusions during follow-up. 63 The same study showed a correlation between the presence of JAK2V617F and a higher leukocyte count. On the contrary, in a series of 117 PMF patients from a single center, Tefferi et al. 64 reported no significant impact of V617F presence on either survival or leukemic transformation, although the presence of the mutation was associated with a history of thrombosis. More recently, a study involving 304 patients with PMF, 63.5% of whom were JAK2V617F mutated, has been reported by Barosi et al. 65 The presence of V617F mutation contributed to laboratory abnormalities, including higher hemoglobin level and leukocyte count, as well as variable platelet count, and to clinical manifestations such as pruritus. One hundred seventy-four patients of this cohort (57%), in whom V617F genotyping had been performed at diagnosis, were prospectively analyzed for outcome using multivariate analysis. The V617F mutational status was associated with an increased risk of death from any cause, leukemic transformation, development of marked splenomegaly, and requirement for splenectomy or chemotherapy. These factors were verified for their independence from other risk factors (including age, sex, hemoglobin level, white blood cell count, peripheral blood blasts and Dupriez score). 65 However, in an even more recent communication from Tefferi et al. 66 in 199 patients with PMF, the results were completely different in that no significant correlation between the presence of V617F and survival, leukemic transformation, or need for chemotherapy or splenectomy was observed. Therefore, unlike in ET, the prognostic relevance of V617F allele in PMF remains controversial.
Homozygosity versus heterozygosity: a rough estimate of V617F allele burden
The first approach that has been employed to address the contribution of mutational load to disease phenotype has been to compare patients who harbored the mutation in the 'heterozygous' or 'homozygous' state; mutational status was defined semiquantitatively on the basis of the amount of mutant allele in the cell population under study (in most instances, gradient-purified granulocytes from peripheral blood): less or greater than 50%, respectively. There are two points that should be taken into account when interpreting the results of studies that are based on these parameters. The first is that in most cases mutational status was defined according to the semiquantitative method of allele-specific PCR, followed by restriction enzyme digestion, described by Baxter et al.;
2 although this is a robust and reproducible approach for routine analysis, it may be unreliable in the correct attribution of patients to either group when the ratio of mutant allele is between 45 to 60% (Vannucchi AM, unpublished data). In fact, the percentage of homozygous patients calculated using quantitative assays might be greater than originally reported. 61 Second, all of the relevant studies in this regard were retrospective, and in most of them the sample used for genotyping had been collected at variable times along the disease course. The time of collection is not expected to affect the final percentage of patients who were mutated or not within each diagnostic group, as there is no substantiated evidence that wild-type patients acquire the V617F allele during the disease course. However, the amount of mutant allele in the cell population used for genotyping may vary with time, particularly in PV and PMF, 34, 65 eventually coincident with disease progression. 34 The largest study that compared V617F heterozygous versus homozygous patients, a collaborative survey from the GIMEMA-MPD group, 61 involved 323 patients with PV (67.8% heterozygous and 32.2% homozygous) and 639 patients with ET (40.2% wild type, 57.6% heterozygous and 2.2% homozygous). In both diseases, homozygosity was associated with stimulated erythropoiesis and myelopoiesis, whereas platelet count was reduced as compared to heterozygous patients. Homozygous patients also displayed a higher incidence of splenomegaly, larger spleen size and need for cytoreductive therapy. One peculiar finding in homozygous PV patients was the high incidence of pruritus (42%). In contrast, no significant difference in the rate and type of major thrombosis was found between heterozygous and homozygous patients with PV, whereas thrombotic events were significantly more frequent among homozygous ET patients compared to either wild type or heterozygous. Hazard ratio for total thrombosis in JAK2V617F homozygous ET patients was 3.97-fold higher than in ET patients who had wild-type JAK2. Arterial thrombosis predominated at diagnosis, whereas arterial and venous thromboses were equally represented during the follow-up. The significant association of homozygosity with cardiovascular events in ET patients was maintained after multivariate analysis, which included as covariates other established risk factors (age 460 years and previous history of thrombosis) 67 as well as leukocytosis (white blood cell counts greater than 8.7 Â 10 9 l À1 ). 68 The aforementioned observations in the GIMEMA study, in regard to PV, were somewhat similar to those from a previous report from the Mayo Clinic 69 that included 45 heterozygote and 13 homozygote PV patients; the latter study reported significantly higher hemoglobin level and incidence of pruritus in homozygous patients but no association with thrombosis. Of note, a significantly higher rate of fibrotic transformation in homozygous versus heterozygous PV patients was reported in both studies (23 
34
The relationship between homozygosity for V617F allele and clinical phenotype in PMF has been evaluated in a series of 193 JAK2V617F mutated patients with PMF, among which 84 were homozygous (27.6% of total patient population) and 109 were heterozygous (35.8%). 65 In this study, V617F homozygosity was independently associated with leukocytosis, larger spleen size, and greater need of cytoreduction. Of interest, it was calculated that conversion from a heterozygous to a homozygous status occurred at a rate of 10 per 100 patient-years; accordingly, homozygous patients had significantly longer disease duration. 65 As a homozygous mutational status was present in the majority of V617F mutated patients who underwent splenectomy (85%) or transformed into acute leukemia (80%), progression from a heterozygous to a homozygous mutational status was interpreted as a factor in the evolution of disease in terms of clinical severity and leukemic transformation. In contrast, Mesa et al. 71 observed a substantial stability of JAK2V617F mutational status over an 18-month period in 44 patients with primary or post-PV/post-ET myelofibrosis; furthermore, in two patients in whom progression from heterozygosity to homozygosity, or from wild type to heterozygosity in an additional one, occurred, no correlation with disease progression could be ascertained.
In summary, the findings of these studies overall indicated that patients having a V617F mutation in the homozygous status are characterized by a more symptomatic myeloproliferative disorder and also established the principle that quantification of mutant allele burden might convey relevant clinical information.
Quantitative assessment of V617F allele burden
Prompted by the results of previous studies in homozygous patients, and owing to the availability of accurate quantitative methods, the hypothesis of a gene-dosage effect on phenotype has been tested in PV and ET and, more recently, in PMF patients. The concept of JAK2V617F 'allele burden' has been introduced as a continuous measure of the ratio between mutant and wild-type alleles in cell non-homogeneous clinical samples employed for genotyping. Figure 1 depicts the distribution of V617F allele burden among the different MPN entities and shows that the lowest and highest values are expressed by patients with ET and post-PV/post-ET myelofibrosis, respectively, whereas the intermediate burden level is found in patients with PV or PMF. 72 By using two comparatively quantitative methods designed for RNA and DNA obtained from peripheral blood granulocytes, the mutant allele burden was prospectively evaluated in 173 PV patients at diagnosis; 73 38 and 18% of patients had greater than 50 and 75% mutant allele, respectively. The burden of V617F allele correlated linearly with measures of stimulated erythropoiesis, including higher hematocrit, lower mean cellular volume, serum ferritin and erythropoietin levels, and of myelopoiesis, such as increased leukocyte and neutrophil count and levels of serum lactate dehydrogenase. Markers of neutrophil activation, such as the level of PRV-1 mRNA and the neutrophil content of leukocyte alkaline phosphatase, were also dose-dependently increased. It was found that patients within the highest quartile, that is, those with greater than 75% mutant allele, displayed a higher incidence of pruritus, palpable splenomegaly, spleen size greater than 15 cm on echo scan, and presented a 3.5-fold higher risk of major thrombosis when compared to the reference group constituted by patients in the lower allele burden category (1-25%); the association with thrombosis was maintained in multivariate analysis that included age, previous thrombosis history and leukocytosis as covariates. Finally, a mutant allele burden greater than 75% represented an independent risk factor for chemotherapy (relative risk, 1.8) after being adjusted for a number of potential covariables. 73 In contrast, Tefferi et al. 74 measured V617F allele burden in bone marrow-derived DNA obtained from 77 PV patients at variable times within 5 years after diagnosis and found that it was correlated with leukocyte count but not with hemoglobin level. Higher allele burden was correlated with pruritus and microvascular symptoms, but not with palpable splenomegaly, cytotoxic therapy or major cardiovascular events. Recently, Silver et al. 75 reported their experience on 105 patients, in whom V617F allele burden was measured by pyrosequencing, unlike by real-time quantitative PCR as in the previous two studies, using DNA from peripheral blood granulocytes collected at variable times following diagnosis. They found that mutational burden not only correlated with leukocytosis, longer disease duration and degree of splenomegaly, but also observed a trend toward more venous events in the highest quintile (greater than 80% mutant allele). Interestingly, a statistically significant correlation with bone marrow fibrosis was also reported. . 72 Results for patients with polycythemia vera (PV) (n ¼ 297), essential thrombocythemia (ET) (n ¼ 382), primary myelofibrosis (PMF) (n ¼ 168) and secondary (post-PV, post-ET) forms of myelofibrosis (sMF; n ¼ 46) are presented. These data are derived from those originally published by Antonioli et al., 72 whereas the population under study has been increased in number (for details about procedures and methods, please refer to original publication 72 ). The level found in ET patients (26 ± 15) was significantly lower than in all other categories: PV (48 ± 26), PMF (72±24) and secondary forms of myelofibrosis (46±30) (Po0.0001). Allele burden in patients with a secondary form of myelofibrosis was also significantly higher than in PV or PMF (Po0.0001 for both). Boxes represent the interquartile range that contains 50% of the subjects, the small square inside the mean value, and the horizontal line inside marks the median; the bars show the upper and the lower range of values.
JAK2V617F allele burden in MPNs AM Vannucchi et al
Although there is a wide range of allele burden values in PV patients, with representative percentages of patients being distributed among the quartiles (Figure 2 ), more than 90% of ET patients belong to the two lower quartiles; this tight distribution of mutant allele load is quite likely a reason why results obtained in ET are even more controversial. Kittur et al. 55 determined V617F allele burden in archived bone marrow DNA collected from 96 mutated ET patients and found direct correlation with platelet and leukocyte count, male gender, palpable splenomegaly and venous thrombosis in the follow-up. There was no difference in allele burden among patients who were evaluated at different time points after diagnosis, pointing to a substantial stability of JAK2V617F clonal load over time in ET, 47 as also observed by Pemmaraju et al. 56 This latter study considered 38 mutated ET patients and found that allele burden in peripheral blood granulocytes correlated neither with minor nor major cardiovascular events. Male patients were characterized by greater mutant allele burden, confirming results from Kittur et al. 55 In contrast, in the largest study in ET patients from Antonioli et al. 62 that included 165 mutated patients, a V617F allele burden greater than 25% was associated with a 3.0-fold higher relative risk of arterial thrombosis at diagnosis in multivariate analysis and a 2.2-fold risk of suffering from microvascular disturbance. Additionally, the risk of having palpable splenomegaly was 2.2-fold higher in the presence of a mutant allele burden greater than 25%. 62 A study addressing clinical correlates of JAK2V617F allele burden in PMF using a quantitative methodology has recently been accomplished at Mayo Clinic. 66 One hundred twenty-nine patients, who had available a sample of bone marrow cells collected at diagnosis or within one year from diagnosis, were genotyped using quantitative real-time PCR. In a multivariate analysis that included the Dupriez prognostic score, it was observed that patients belonging to the lowest quartile had significantly shortened overall and leukemia-free survival compared to those with either higher mutant allele burden or without the mutation. The intriguing conclusion from this study is that PMF patients having a larger JAK2V617F positive clone would be less prone to leukemic transformation, in contrast with the observation that 80% of leukemic transformations among JAK2-mutated patients occurred in those with greater than 50% mutant allele in the study by Barosi et al.
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Assessment of V617F allele burden: potential sources of variability Among the several potential variables that might account for the discrepancies in the above referenced studies, one should also consider, in addition to different patient series, the analytical strategy as well as the cell sources of genetic material that have been employed for genotyping. Although first studies used direct sequencing, which is a low-sensitivity (threshold level is around 10-20% mutant allele), high-specificity technique, the allelespecific oligonucleotide-PCR technique developed by Baxter et al. 2 has been almost universally employed in most of the studies, including the large series from GIMEMA. 65, 61 In contrast, in almost each of the studies that quantitatively measured V617F allele burden, a unique, in-house developed method was employed that differed each from the other as JAK2V617F allele burden in MPNs AM Vannucchi et al concerns the type of analytical technique (pyrosequencing, realtime quantitative PCR, analysis of melting curve), the design and labeling of the primer/probe (conventional TaqMan primer/ probe or locked nucleic acid-LNA probe) and in the reagents employed as reference for quantification (mutant cell lines, plasmids, DNA from homozygous patients). As a matter of fact, there is no comparative evaluation of their respective performance, and the issue arises whether and how much they are comparable and how this might have affected the results reported in regard to clinical correlates. 76, 77 To date, there is no information about a possible role for measuring the JAK2V617F transcript level as a prognostic factor in MPNs that is alternative or complementary to mutant allele quantification. In a comparative analysis 73 of two quantitative methods employing cDNA 32 and gDNA, respectively, we found a strong correlation between the two assays performed in the same granulocyte preparation, a finding also confirmed by others. 42, 78 Therefore, the ratio of mutant to wild-type JAK2V617F is comparable irrespective of which nucleic acid is employed for quantification, although the expression of total JAK2 (wild-type plus mutant one) was found to be slightly higher in PV and PMF patients than in ET. 42 In all the above studies, the cell population employed for measuring mutant allele burden was represented by peripheral blood granulocytes or archival bone marrow cells, which are probably equivalent. 79 As a matter of fact, in case of ET, the reported median allele burden was 6.3% in one study that employed bone marrow DNA, 55 7% (range 1-39%) in a series of 21 mutated patients whose DNA was prepared from unfractionated peripheral blood leukocytes, 70 and 24% (range 1-87%) 62 and 43% (range 11-64%) 56 in two studies where purified granulocytes were used. Whether these differences originated from variable patient characteristics, the analytical method employed and/or the indifferent use of whole blood, purified granulocytes or bone marrow aspirates remains to be ascertained; this issue may have relevance particularly in case of PMF where aspirates might not be fully representative of hematopoietic cellularity due to fibrosis. Furthermore, recent data would suggest that circulating purified CD34 þ cells are a more appropriate cellular source for correlative studies. Moliterno et al. 80 observed that the burden measured in peripheral blood granulocytes was 1.56-and 1.14-fold higher, respectively, in PV and ET than in the CD34 þ cells, unlike in PMF where the two measurements were comparable. On this ground, they introduced the concept of 'clonal dominance' to indicate those patients who displayed a difference between granulocytes and CD34 þ cells in the percentage of V617F allele equal to or less than 10; clonal dominance was found in 22% of ET, 53% of PV and 90% of PMF patients. The authors not only found a strong correlation of the burden measured in CD34 þ cells with disease features (hemoglobin, leukocytosis, spleen size, disease duration) but also found that clonally dominant PV patients had more symptomatic disease, even though their V617F burden in granulocytes was similar to non-clonally dominant patients. Therefore, they suggested that the burden measured in CD34 þ cells, rather than that in granulocytes, should be considered for clinical correlates; however, while of interest, these observations need to be validated in other studies, and it should also be mentioned that measuring V617F allele burden in purified CD34 þ cells is probably not easy to implement in routine diagnostics, although it might be more appropriate in the setting of prospective clinical trials.
Finally, an additional source of variability is represented by the design of published clinical studies, which included a heterogeneous series of patients as concerned diagnostic criteria (PVSG and WHO criteria), was retrospective in most instances and included patients with wide time intervals from diagnosis to genotyping. At this regard, the progression to increasing allelic burden that has been reported in PMF patients, 65 unlike in ET, 47 should be kept in consideration when allele burden values are correlated with hematologic or clinical variables recorded at diagnosis and/or are used as prognostic risk factors for survival or leukemia transformation. Also, the relatively low frequency of target events might limit the interpretation of studies with small sample size. For example, a plausible explanation for the conflicting results about a possible correlation between allele burden and thrombotic risk in ET might be the relatively small number of mutated patients analyzed in the studies, which ranged from 38 56 to 165 62 and included from 10 56 to 42 55 patients suffering from major cardiovascular events. Furthermore, it is difficult to control these studies in regard to treatment, which might have affected the overall outcome. This contention is exemplified by the different fate of mutant ET patients treated with hydroxyurea or anagrelide in the PT-1 trial.
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Assessment of V617F allele burden as a mean to measure response to therapy
Further insights into the correlation between mutant allele burden and phenotype have been obtained from the measurement of mutant allele load in patients undergoing different therapeutic strategies. Jones et al. 81 took advantage of quantitative assessment of V617F allele to evaluate the effect of rIFNa and imatinib in 14 and 7 PV patients, respectively. They found a two-to threefold reduction in the median percentage of mutant alleles both in peripheral blood and in bone marrow that correlated with hematological response. Patients with imatinib or IFN-induced complete remission had lower allele burden as compared to those who did not achieve complete remission. Prospective sequential evaluation of V617F allele in a multicentric phase 2 trial of pegylate-interferona-2a in younger PV patients has been performed by Kiladjian et al. 82 Eighty-nine percent of evaluable patients presented a decrease of JAK2V617F mutant allele from a mean of 49 to 27%. In 12 patients, the reduction of JAK2V617F burden was coincident with hematological response, whereas in the remaining 8 patients a molecular response was obtained only after prolonged treatment. A significant decrease of bone marrow JAK2V617 allele burden, associated with hematologic improvement, has been observed in three patients with post-PV MF and a del(5)(q31) abnormality who were treated with lenalidomide. 83 In contrast, an apparently complete molecular response obtained after INFa-2a treatment in a case of chronic eosinophilic leukemia harboring JAK2V617F was not associated with signs of hematological improvement. 84 Finally, Kroger et al. 85 employed a very highly sensitive PCR assay to monitor JAK2V617F mutant cells after reduced dose-intensity allogeneic stem cell transplantation in 21 patients with myelofibrosis. In 78% of the patients, a complete molecular response was obtained, and in those patients who eventually relapsed, variation of V617F allele burden correlated with the clinical course. Therefore, these observations indicate that changes in V617F allele burden and clinical manifestation of the disease are tightly associated in most instances. However, one cannot conclude, as yet, that modest reductions in V617F allele burden indicate clinical benefit.
Concluding remarks
Different studies from different investigators have produced variable results regarding the prognostic relevance of JAK2V617F allele burden in PV, ET and PMF, and notwithstanding an increasing body of evidence especially in patients with PV, 86 no definite conclusion can be made at this point. This issue is also of potential importance considering the prospect of anti-JAK2-targeted therapy. 87 Additional and preferably prospective studies using similar methodology, in terms of cell source and allele burden measurement, are needed to resolve the issue at hand and reach a definite and shared statement, also considering the prognostic interaction between JAK2V617F and other risk factors, such as leukocytosis. 68, 88, 89 
